Want to see AHCO full AI Analyst Report?
AHCO Stock Chart & Stats
$12.66
$0.16(1.59%)
At close: 4:00 PM EST
$12.66
$0.16(1.59%)
Day’s Range― - ―
52-Week Range$8.51 - $13.43
Previous CloseN/A
Volume245.49K
Average Volume (3M)1.42M
Market Cap
$1.44B
Enterprise Value$3.58K
Total Cash (Recent Filing)$47.96M
Total Debt (Recent Filing)$2.00B
Price to Earnings (P/E)―
Beta0.30
Next Earnings
Aug 04, 2026EPS Estimate
0.15Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.59
Shares Outstanding136,054,150
10 Day Avg. Volume967,197
30 Day Avg. Volume1,419,251
Financial Highlights & Ratios
PEG Ratio0.10
Price to Book (P/B)0.89
Price to Sales (P/S)0.41
P/FCF Ratio6.14
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$14.17Price Target Upside11.90% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.84
Revenue Forecast (FY)$3.48B
Bulls Say, Bears Say
Bulls Say
Large Capitated Contract WinThe multi-million member capitated win creates a durable, contracted revenue stream and accelerates scale in HME delivery. Exclusive provider status to >10M members and ~15M capitated membership should increase recurring resupply sales and utilization-based revenue as the rollout fully ramps.
Recurring Revenue And Organic GrowthSustained organic growth driven by Sleep and Respiratory shows the underlying business model of recurring resupply and device follow-on purchases is intact. Consistent revenue expansion supports long-term cash generation from installed patient bases and mitigates single-period volatility.
Refinancing Strengthens LiquidityThe $1.1B facility plus term/delayed-draw structure extends maturities, lowers funding costs and increases revolver capacity. This durable financing flexibility reduces near-term refinancing risk, supports working capital/CapEx for capitated rollout and improves the company's ability to execute M&A.
Bears Say
Elevated Leverage And Net LossesPersistent debt loads and recent net losses leave the capital structure exposed: elevated leverage (~3.0x reported) combined with negative ROE in 2025/TTM constrains strategic flexibility. Sustained profitability improvement is required to materially de-risk credit profile and restore shareholder returns.
Margin Pressure And Earnings VolatilityDeteriorating gross margins and inconsistent profitability indicate structural cost or pricing pressure. Even with operating profit returns in pockets, below-the-line volatility and margin compression raise the risk that cash flow conversion will remain uneven until structural cost or reimbursement dynamics improve.
CapEx And Near-Term Free Cash Flow DragHigh inventory and equipment stocking to support capitated members drove elevated CapEx and negative Q1 FCF. While management expects normalization, the material upfront cash outlay pressures leverage and liquidity in the medium term and delays the conversion of contract revenue into free cash flow.
AdaptHealth News
AHCO FAQ
What was Adapthealth’s price range in the past 12 months?
Adapthealth lowest stock price was $8.51 and its highest was $13.43 in the past 12 months.
What is Adapthealth’s market cap?
Adapthealth’s market cap is $1.44B.
When is Adapthealth’s upcoming earnings report date?
Adapthealth’s upcoming earnings report date is Aug 04, 2026 which is in 18 days.
How were Adapthealth’s earnings last quarter?
Adapthealth released its earnings results on May 05, 2026. The company reported -$0.056 earnings per share for the quarter, missing the consensus estimate of $0.012 by -$0.068.
Is Adapthealth overvalued?
According to Wall Street analysts Adapthealth’s price is currently Undervalued.
Does Adapthealth pay dividends?
Adapthealth does not currently pay dividends.
What is Adapthealth’s EPS estimate?
Adapthealth’s EPS estimate is 0.15.
How many shares outstanding does Adapthealth have?
Adapthealth has 136,054,150 shares outstanding.
What happened to Adapthealth’s price movement after its last earnings report?
Adapthealth reported an EPS of -$0.056 in its last earnings report, missing expectations of $0.012. Following the earnings report the stock price went down -9.893%.
Which hedge fund is a major shareholder of Adapthealth?
Currently, no hedge funds are holding shares in AHCO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
AdaptHealth Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$14.17 (11.90% Upside)
$14.17 (11.90% Upside)
Blogger Sentiment
Bullish
AHCO Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 121.1K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.8%
Last 30 Days ▲ 0.8%
Last 30 Days ▲ 0.8%
Technicals
SMA
Negative
20 days / 200 days
Momentum
19.38%
12-Months-Change
Fundamentals
Return on Equity
-5.11%
Trailing 12-Months
Asset Growth
-0.30%
Trailing 12-Months
Company Description
Adapthealth
AdaptHealth Corp., alongside its network of subsidiaries, delivers a comprehensive range of home medical equipment (HME), supplies, and associated services across the United States. The company specializes in sleep therapy, providing CPAP and bi-PAP devices and support for individuals managing obstructive sleep apnea. It also furnishes essential medical devices and provisions for diabetes treatment, such as continuous glucose monitors and insulin pumps. AdaptHealth supplies HME to patients transitioning from acute care settings, offers in-home oxygen and chronic therapy services, and caters to chronically ill patients with specialized equipment and supplies for wound care, urological, incontinence, ostomy, and nutritional needs. These services are accessible to beneficiaries of Medicare, Medicaid, and various commercial insurance payors. AdaptHealth Corp. is primarily based in Plymouth Meeting, Pennsylvania.
AHCO Stock 12 Month Forecast
Average Price Target
$14.17
▲(11.90% Upside)
Technical Analysis
Ownership Overview
15.12% Insiders
23.32% Mutual Funds
5.84% Other Institutional Investors
31.78% Public Companies and
Individual Investors